The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy)

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 15, 2015

Primary Completion Date

August 15, 2018

Study Completion Date

December 15, 2018

Conditions
Hibernation, MyocardialComplete Occlusion of Coronary Artery
Interventions
DEVICE

stenting or balloon expansion

all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)

DRUG

aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc

Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.

All Listed Sponsors
collaborator

Beijing Anzhen Hospital

OTHER

collaborator

First Hospital of China Medical University

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

lead

The First Affiliated Hospital of Dalian Medical University

OTHER

NCT02767401 - The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) | Biotech Hunter | Biotech Hunter